Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

The Depression Test
There is a frenzied push by mental health providers--almost all of whom have
generic viagra online
UK Conductor And HIs Wife End Their Own Lives At Swiss Assisted Suicide Clinic
A well known UK orchestra conductor Sir Edward Thomas Downes, CBE, and his wife Lady Joan Downes have died after choosing to end their
News of the day
Vaxart Begins Animal Testing Of H1N1 Flu Vaccine Candidate
Vaxart, Inc., a biotechnology company focused on the development of oral vaccines, announced today that the company has created a candidate vaccine for H1N1 influenza (swine flu). On Saturday, May 23, Vaxart began testing for immune responses in animals, just 25 days after initiating the project. The company will compare performance of the research-grade H1N1 vaccine to its successful avian flu vaccine as a first step towards potential human clinical testing.
Health Insurance

BioElectronics Prepares For General Surgical Recovery FDA 510(k) Premarketing Application Submission

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced the Company is currently preparing an application for 510(k) premarket notification for submission to the Food and Drug Administration (FDA) for general surgical recovery. The filing will request an indication for the adjunct of use in palliative treatment of postoperative edema and pain in superficial soft tissue. "There is overwhelming clinical data demonstrating the application of PEMF therapy significantly reduces postsurgical edema (swelling), pain and speeds healing. There are currently several devices cleared for this indication of use, but these devices are very large, expensive and are in no way portable, so they are neither practical nor marketable for surgical recovery. BioElectronics" portable version of PEMF, for which we recently were granted a patent, is very different. Our biomedical engineers have been able to shrink PEMF technology into a wearable patch that can be applied directly over the site of surgery," commented Andrew Whelan, CEO of BioElectronics. "Many surgeons are already using our products as an adjunctive therapy in the post-operative environment to speed healing and to significantly reduce, or in many cases, completely eliminate the use of narcotics, Tylenol® or acetaminophen, and NSAIDs to control surgical related pain within their patient populations." BioElectronics Corp."s RecoveryRX™ devices have already received FDA clearance for the treatment of edema following blepharoplasty, a common plastic surgery procedure. Gaining this additional FDA indication will allow the Company to market its products for use in the general surgical market, which consists of hundreds of thousands of procedures performed each year in both the ambulatory and outpatient environments. The Company recently filed with FDA for clearance to market its Allay™ Menstrual Pain Relief Patch product and is currently in process of completing numerous clinical trials designed to support additional marketing clearance applications with FDA. BioElectronics Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009